Showing 161-170 of 333 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| GeLite: Glowing Engineered Luminescent Microgels for Transplant Evaluation | Regents of the University of Michigan | Maria Coronel | Cures | 01-June-2024 to 30-April-2026 | $200,000.00 |
| Longitudinal non-inasive monitoring of vascular remodeling using oxygen-sensing nanoprobes | Regents of the University of Michigan | Maria Coronel | Cures | 01-March-2025 to 28-February-2030 | $1,000,000.00 |
| University of Michigan and OHSU Breakthrough T1D Cardio-Renal Center of Excellence : Accelerating Breakthrough Targeted New Therapies for Cardio-Renal Complications for People with T1D | Regents of the University of Michigan | Matthias Kretzler | Improving Lives | 01-May-2025 to 30-April-2028 | $2,842,434.27 |
| Eye biorepository: A hub for the restoring vision moonshot | Regents of the University of Michigan | Patrice Fort | Improving Lives | 01-March-2025 to 28-February-2026 | $218,095.83 |
| Repurposing LRRK2 inhibitors for β cell protection in T1D | Regents of the University of Michigan | Scott Soleimanpour | Cures | 01-September-2023 to 31-August-2026 | $750,000.00 |
| JDRF and M-Diabetes Center of Excellence at the University of Michigan | Regents of the University of Michigan | Thomas Gardner | Cures | 01-October-2019 to 30-September-2025 | $7,795,943.05 |
| Hybrid Closed Loop Therapy for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study (CLVerEX) | Regents of the University of Minnesota | Antoinette Moran | Cures | 01-April-2023 to 31-March-2026 | $1,739,442.00 |
| Mechanistic Etiologies Underlying the Impact of Verapamil to Preserve β Cell Function in Type 1 diabetes | Regents of the University of Minnesota | Antoinette Moran | Cures | 01-September-2024 to 31-August-2026 | $643,946.00 |
| Growing Beta Cell Replacement in T1D by Tolerizing Stem Cell-Derived Islets | Regents of the University of Minnesota | Bernhard Hering | Cures | 01-August-2025 to 31-July-2027 | $688,430.02 |
| Preclinical development of a combinatorial therapy with a humanized antibody to serpinB13 in type 1 diabetes | Regents of the University of Minnesota | Jan Czyzyk | Cures | 01-June-2022 to 31-May-2025 | $765,000.00 |